|05th December,2018||2:00-3:30 pm||Track 3|
All of these non-dilutive financing sources are becoming increasingly numerous thanks both to the emergence of interest expressed by many trusts and foundations in financing innovative start-ups and to the many governmental schemes that are devoted to financing the first steps of biotech start-ups. How do these sources of revenue lead to real leverage effect or create constraints for the companies? What types of constraints do they expose biotech entrepreneurs to?
Anjan Aralihalli - CTI Life Sciences Fund II